Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CASI Pharmaceuticals, Inc. (CASI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6424-0.0298 (-4.43%)
At close: 04:00PM EST
0.6600 +0.02 (+2.74%)
After hours: 06:53PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close0.6722
Open0.6600
Bid0.6600 x 1100
Ask0.6700 x 900
Day's Range0.6351 - 0.6772
52 Week Range0.6351 - 3.9000
Volume1,259,347
Avg. Volume1,225,514
Market Cap89.806M
Beta (5Y Monthly)0.33
PE Ratio (TTM)N/A
EPS (TTM)-0.3440
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.45
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CASI

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CASI Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/22/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • Benzinga

    Casi Pharma-Partnered BioInvent's Lead Cancer Program Gets FDA Orphan Drug Tag

    The FDA has granted Orphan Drug Designation to BioInvent International AB's (OTC: BOVNF) BI-1206, an anti-FcyRllB antibody, for follicular lymphoma (FL) the most common form of Non-Hodgkin lymphoma (NHL). BioInvent is a collaborating partner of CASI Pharmaceuticals Inc (NASDAQ: CASI). BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials. One trial is evaluating the BI-1206 combination with rituximab for Non-Hodgkin lymphoma in patients who have r

  • PR Newswire

    CASI PHARMACEUTICALS PARTNER, BIOINVENT, ANNOUNCES BI -1206 GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA

    CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced today, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its partner BioInvent International AB, for BI-1206, an investigational anti-FcyRllB antibody, for the treatment of follicular lymphoma (FL), the most common form of slow-growing Non-Hodgkin lymphoma (NHL).

  • PR Newswire

    CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA

    CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced today, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its partner Juventas Cell Therapy Ltd (Juventas), for CNCT19, an investigational CD-19 directed CAR-T therapy, for the treatment of patients with Acute Lymphoblastic Leukemia (ALL).

Advertisement
Advertisement